Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Share-based Compensation of $556000.0 for Q1 2026, up 18.8% on a YoY basis from $468000.0 in Q1 2025, and down 20.11% quarter-over-quarter from $696000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Share-based Compensation for 7 years, with the latest figure at $556000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 18.8% year-over-year to $556000.0; the trailing twelve-month figure through Mar 2026 stood at $556000.0 (down 84.39% YoY), and the FY2025 full-year result was $468000.0, down 90.06% from the prior year.
- Share-based Compensation for Q1 2026 stood at $556000.0, down from $696000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $4.0 million in Q1 2022, with the low at -$415000.0 in Q3 2025.
- Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 1907.02% — and 2025, when it tumbled 136.28%.
- Barinthus Biotherapeutics' Share-based Compensation stood at $2.0 million in 2022, then tumbled by 61.49% to $786000.0 in 2023, then decreased by 3.94% to $755000.0 in 2024, then fell by 7.81% to $696000.0 in 2025, then fell by 20.11% to $556000.0 in 2026.
- The last three Share-based Compensation figures came in at $556000.0 (Q1 2026), $696000.0 (Q4 2025), and -$415000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | 556,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 556,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Dec 31, 2025 | 696,000.00 |
| Dec 31, 2025 | 696,000.00 |
| Sep 30, 2025 | -415,000.00 |
| Sep 30, 2025 | -415,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 755,000.00 |
| Dec 31, 2024 | 755,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 786,000.00 |
| Dec 31, 2023 | 786,000.00 |